Skip to content

Evaluation of the clinical application effect of ventilator intelligent synchronization technology

Evaluation of the clinical application effect of ventilator intelligent synchronization technology

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098224
Enrollment
Unknown
Registered
2025-03-04
Start date
2025-03-05
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Interventions

Group A :Phase 1 intervention (IntelliCycle+SIMV mode, 2 hours): The first hour is the preparation period The second hour was the study period, and patient data were recorded, including respiratory ra
Group B:Phase 1 intervention (SIMV mode, 2 hours): The first hour is the preparation period The second hour is the study period, and relevant data are recorded. Washout period (1 hour): Same as above,

Sponsors

Huashan Hospital, Fudan University, Shanghai, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Spontaneously breathing mechanically ventilated patients undergoing endotracheal intubation or tracheostomy; 2. The oxygenation index is 150-300mmHg; 3. 18 years old< = age<80 years old, regardless of gender; 4. 18kg/m^2<=BMI<=30 kg/m^2; 5. Patients or their families will fully understand the purpose and significance of the trial, voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who will be sedated in the general ward for > 3 days before being transferred to the ICU or in the ICU before signing the informed consent form; 2. Have a history or evidence that they are at increased risk during sedation/anesthesia during the screening period; 3. Pregnant and lactating women; 4. Patients with hypoxemia caused by pulmonary embolism, pneumothorax, airway obstruction, etc 5. Patients with hemodynamic disorders, patients with myocardial ischemia, intracranial hypertension, malignant tumors, and tuberculosis 6. Participated in other clinical trials within 1 month before screening. 7. The investigators decide that the patient is not eligible for inclusion in the clinical trial for a variety of reasons.

Design outcomes

Primary

MeasureTime frame
Work of breath;

Secondary

MeasureTime frame
Respiratory Rate;Heart Rate;

Countries

China

Contacts

Public ContactFeng Zhao, Weijia Li

Huashan Hospital, Fudan University, Shanghai, China.

zficu@163.com+86 138 1627 7978

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026